BioReference executes COVID-19 testing program for NBA and NHL for 2020-21 seasons, as well as U.S. Women’s and Men’s National Soccer Teams, Winter X Games and NBA G League ELMWOOD PARK, N.J., January 26, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced COVID-19 testing agreements for players and officials, as well […]
Tag Archives: opko
Press Release
OPKO Health’s BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health Access
13
Jan
Jan
Scarlet brings diagnostic service to patients’ homes, offices and other preferred locations, delivering an on-demand, safe and convenient diagnostic experience for patients and healthcare providers ELMWOOD PARK, N.J., January 13, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today introduced Scarlet Health™, an in-home, fully integrated digital platform providing access to on-demand diagnostic […]
Press Release
OPKO Health’s BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide
04
Jan
Jan
Nearly 210,000 New York City students, teachers, principals and staff were tested by BioReference with a positivity rate of 0.47% ELMWOOD PARK, N.J., (January 4, 2021) – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR tests for public schools throughout New York City’s boroughs, with a positivity rate of […]
Press Release
Buffalo Bills and OPKO Health’s BioReference Laboratories Initiate the First Large Scale, Mandatory COVID-19 Fan Testing Program
31
Dec
Dec
The Bills leverage testing capabilities from NFL testing provider, BioReference, to initiate fan testing program ORCHARD PARK, N.Y., December 31, 2020 – Buffalo Bills, 2020 AFC East Division Champions, and BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced they will be performing fan testing for the AFC Divisional Wild Card playoff game at […]
Press Release
OPKO Health’s BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test
20
Oct
Oct
New offering identifies COVID-19 and Influenza infections with a single sample ELMWOOD PARK, N.J., October 20, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the United States, to aid in the […]
Press Release
OPKO Health’s BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools
09
Oct
Oct
Through New York City, BioReference will be testing students, teachers and staff in nearly 1,000 NYC public schools ELMWOOD PARK, N.J., October 9, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school […]
Press Release
OPKO Health’s BioReference Laboratories Announces New York City Schools COVID-19 Testing Program
02
Sep
Sep
The COVID-19 testing program will test principals, teachers and staff in preparation for a safer back-to-school environment ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today began testing New York City principals, teachers and other staff for COVID-19, across the five boroughs, in preparation for a safer back-to-school environment. Through a […]
Press Release
OPKO Health’s BioReference Laboratories Launches Best-in-Class Next-Generation Sequencing (NGS) Assay
01
Sep
Sep
ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), along with its specialty oncology division, GenPath, today announced the launch of OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay that enables revolutionary deoxyribonucleic acid (DNA) mutational profiling of tumor samples. OnkoSight AdvancedNGS testing provides targeted gene content that is aligned with the latest […]
ELMWOOD PARK, N.J., August 18, 2020 – BioReference Laboratories Inc., an OPKO Health Company, is pleased to announce it is now in-network with all Blue Cross and Blue Shield of Texas (BCBSTX) products, including its Health Maintenance Organization (HMO) and Medicaid lines of business. The contract includes BioReference’s subsidiary GeneDx, Inc., a full service genetics […]
News
OPKO Health’s GeneDx Enters into Agreement with Pediatrix Medical Group to Offer Neonatal Genomic Services
12
Aug
Aug
GAITHERSBURG, Md., August 12, 2020 – GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), the global leader in neonatal and pediatric genetic testing, announced the entrance into an agreement with Pediatrix Medical Group (“Pediatrix”), the nation’s leading provider of maternal-fetal, and pediatric medical and surgical subspecialty physician services, to offer state-of-the-art, […]